These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16396766)

  • 1. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
    Raza A; Lisak L; Billmeier J; Pervaiz H; Mumtaz M; Gohar S; Wahid K; Galili N
    Leuk Lymphoma; 2006 Mar; 47(3):433-40. PubMed ID: 16396766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
    Vaena DA; Walker P; Pennington K; Stephens A; Stender MJ; Yiannoutsos CT; Young C; Stoner C; Cripe LD;
    Leuk Res; 2004 Jan; 28(1):49-52. PubMed ID: 14630080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
    Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Estey E; O'Brien S; Cortes J; Koller CA; Giles FJ; Kornblau S; Andreeff M; Vey N; Pierce SR; Hayes K; Wong GC; Keating M; Kantarjian H
    J Clin Oncol; 1999 Sep; 17(9):2819-30. PubMed ID: 10561358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
    Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
    Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan in the treatment of hematologic malignancies.
    Beran M; Kantarjian H
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
    Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
    Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes].
    Xu ZF; Qin TJ; Zhang Y; Liu KQ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):451-5. PubMed ID: 21122398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
    Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
    Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
    Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
    Cancer; 2006 Aug; 107(4):767-72. PubMed ID: 16826578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
    Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
    Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
    Grinblatt DL; Yu D; Hars V; Vardiman JW; Powell BL; Nattam S; Silverman LR; de Castro C; Stone RM; Bloomfield CD; Larson RA;
    Cancer; 2009 Jan; 115(1):84-93. PubMed ID: 19025972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
    Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
    Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
    Phippen NT; Leath CA
    J Reprod Med; 2009 Sep; 54(9):583-6. PubMed ID: 19947038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.